Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Neuronetics ( (STIM) ) has released its Q3 earnings. Here is a breakdown of the information Neuronetics presented to its investors.

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

Tiara Gray was diagnosed with 3 mental conditions, including bordeline personality disorder. Yet the Navy kept her in a high-pressure job.

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising Phase 2 results, Cybin’s PARADIGM program has begun with significant funding ...

The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement ...

BUFFALO, N.Y. — University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication, often described as a wonder drug, ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...